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Cryo Balloon
Pulmonary Vein Isolation
Is it Really All So “Simple”?*
Sabine Ernst, MD
London, United Kingdom
Since the seminal observation of an atrial fibrillation (AF)-
initiating trigger mostly originating from the pulmonary
veins (PVs), techniques to reproducibly achieve electrical
PV isolation have been investigated (1). The time-
consuming, point-by-point radiofrequency ablation tech-
nique was challenged by using novel technologies aiming for
a tantalizing “single-shot” approach to facilitate and speed
up the invasive procedure.
See pages 1707 and 1713
More than 10 years ago, the pursuit for novel tools to
perform PV isolation in a reproducible and simple, single
procedure was initiated. In this issue of the Journal, the
results of 2 major trials on cryoballoon catheter–guided PV
isolation are published that highlight the increasing urge to
facilitate the curatively intended procedure to treat drug-
refractory AF (2,3). Although Vogt et al. (2) report their
single-center experience on 605 patients with mostly par-
oxysmal AF (96%), Packer et al. (3) report on the outcome
of a multicenter, prospective trial conducted in the United
States and Canada (n  245; total of 26 centers) on either
aroxysmal AF (78%) or early persistent AF (22%). Interest-
ngly, the clinical outcome after a single procedure was not
ramatically different (61.6% in the single-center trial vs.
7.7% in the multicenter trial). This finding is noteworthy in
he fact that with increasing experience of the user, the
utcome does seem not to improve but rather reaches a plateau.
In Vogt et al. (2), the best outcome was achieved when
oth small (23 mm) and large (28 mm) diameter balloons
ere used (47.7% of all patients). This is most likely due to
he inability of the balloon devices to adapt to the individual
V ostial anatomy. Although using different balloons im-
roved the ablation outcome, it also doubled the costs of the
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imaging (magnetic resonance imaging scans or PV angiog-
raphy) even when used by very experienced operators. In the
multicenter experience (with some of the participating
centers contributing only a few patients) (3), this effect was
even more pronounced. Notably, the average procedure time
and fluoroscopy exposure in the single-center trial
amounted to 156 min and 25.2 min, respectively, but was
significantly longer in the multicenter trial (371 and 66 min,
respectively). This reflects on the difficulty (rather than the
simplicity) of performing this allegedly “simple” procedure
even by otherwise experienced electrophysiology operators.
Conversely, good procedural parameters can be achieved
once the learning curve is finished and a center accepts a
given tool as their standard approach.
Although some technologies (such as various ultrasound
balloons [4,5]) initially created a lot of enthusiasm in the EP
scene, few (if any) have kept their promise to be indeed
simpler, more effective, and at least equally safe. All avail-
able novel devices have eventually “produced” major com-
plications, some of them disastrous or initially not recog-
nized (6,7). Although radiofrequency energy is also not a
safe energy, cryoenergy (as much as many other alternative
energies) has been reported to be potentially (more) harmful
or, at the very minimum, not fool-prove (8–11). Not
surprisingly, the single-center experience (2) demonstrated a
relatively low complication rate compared with the results of
the multicenter trial (3). However, phrenic nerve palsy
features very prominently, which cannot be completely
avoided by using larger balloons. With the results of the 2
now-published trials, cryoablation does not seem to be a
contender to open the AF ablation field yet to non-
electrophysiologists. When used by experienced EP opera-
tors at the beginning of their learning curve with the device
(multicenter trial), a substantial number of serious compli-
cations were observed (3).
Simultaneous mapping systems are currently shining a
new light on AF, improving our understanding of the role
of the PVs (as trigger sites) and the atria (for both trigger
sites and maintenance of AF) (12–14). Although extra-PV
triggers have thus far been reported to be relatively rare, the
simultaneous mapping systems allow a quasi- “satellite-
perspective” to observe the phenomenon during ongoing
AF. They demonstrate surprisingly simple patterns that
resemble hurricanes on weather forecast maps, which
seemed to be successfully eliminated by non–PV-isolating
ablation (12). If these observations are confirmed in larger
trials by multiple operators, then one could even speculate
on a potential decline in the need for PV isolation for AF
ablation in years to come.
The challenge of a truly simple ablation tool that will quickly
and effectively isolate PVs has not yet been solved. Although
single-procedure results are somewhat sobering, the procedure
itself does not become easier after a few cases but seems to
require completion of a substantial learning curve.
1725JACC Vol. 61, No. 16, 2013 Ernst
April 23, 2013:1724–5 Cryoballoon Pulmonary Vein IsolationReprint requests and correspondence: Dr. Sabine Ernst, Na-
tional Heart and Lung Institute, Imperial College, Royal Bromp-
ton and Harefield Hospital, Sydney Street, SW3 6NP London,
United Kingdom. E-mail: s.ernst@rbht.nhs.uk.
REFERENCES
1. Jais P, Haissaguerre M, Shah DC, et al. A focal source of atrial
fibrillation treated by discrete radiofrequency ablation. Circulation
1997;95:572–6.
2. Vogt J, Heintze J, Gutleben KJ, Muntean B, Horstkotte D, Nölker G.
Long-term outcomes after cryoballoon pulmonary vein isolation:
results from a prospective study in 605 patients. J Am Coll Cardiol
2013;61:1707–12.
3. Packer DL, Kowal RC, Wheelan KR, et al., for the STOP AF
Cryoablation Investigators. Cryoballoon ablation of pulmonary veins
for paroxysmal atrial fibrillation: first results of the North American
Arctic Front (STOP-AF) pivotal trial. J Am Coll Cardiol 2013;61:
1713–23.
4. Natale A, Pisano E, Shewchik J, et al. First human experience with
pulmonary vein isolation using a through-the-balloon circumferential
ultrasound ablation system for recurrent atrial fibrillation. Circulation
2000;102:1879–82.
5. Nakagawa H, Antz M, Wong T, et al. Initial experience using a
forward directed, high-intensity focused ultrasound balloon catheter
for pulmonary vein antrum isolation in patients with atrial fibrillation.
J Cardiol Electrophysiol 2007;18:136–44.
6. Neven K, Schmidt B, Metzner A, et al. Fatal end of a safety algorithm
for pulmonary vein isolation with use of high-intensity focused
ultrasound. Circ Arrhythm Electrophysiol 2010;3:260–5.7. Ernst S, Ouyang F, Goya M, et al. Total pulmonary vein occlusion as
a consequence of catheter ablation for atrial fibrillation mimicking
primary lung disease. J Cardiovasc Electrophysiol 2003;14:366–70.
8. Guiot A, Savoure A, Godin B, Anselme F. Collateral nervous damages
after cryoballoon pulmonary vein isolation. J Cardiovasc Electrophysiol
2012;23:346–51.
9. Herrera Siklody C, Deneke T, Hocini M, et al. Incidence of
asymptomatic intracranial embolic events after pulmonary vein isola-
tion: comparison of different atrial fibrillation ablation technologies in
a multicenter study. J Am Coll Cardiol 2011;58:681–8.
10. Stockigt F, Schrickel JW, Andrie R, Lickfett L. Atrioesophageal
fistula after cryoballoon pulmonary vein isolation. J Cardiovasc Elec-
trophysiol 2012;23:1254–7.
11. van Opstal JM, Timmermans C, Blaauw Y, Pison L. Bronchial
erosion and hemoptysis after pulmonary vein isolation by cryoballoon
ablation. Heart Rhythm 2011;8:1459.
12. Narayan SM, Krummen DE, Shivkumar K, Clopton P, Rappel WJ,
Miller JM. Treatment of atrial fibrillation by the ablation of localized
sources: CONFIRM (Conventional Ablation for Atrial Fibrillation
With or Without Focal Impulse and Rotor Modulation) trial. J Am
Coll Cardiol 2012;60:628–36.
13. Shivkumar K, Ellenbogen KA, Hummel JD, Miller JM, Steinberg JS.
Acute termination of human atrial fibrillation by identification and
catheter ablation of localized rotors and sources: first multicenter
experience of focal impulse and rotor modulation (FIRM) ablation.
J Cardiovasc Electrophysiol 2012;23:1277–85.
14. Cuculich PS, Wang Y, Lindsay BD, et al. Noninvasive characteriza-
tion of epicardial activation in humans with diverse atrial fibrillation
patterns. Circulation 2010;122:1364–72.Key Words: atrial fibrillation y catheter ablation y cryoballoon ablation.
